Literature DB >> 8526997

Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor.

H Tohgi1, T Abe, S Takahashi, M Saheki, M Kimura.   

Abstract

We studied changes in the concentrations of serotonin (5-HT), kynurenine, and other indoleamines in the cerebrospinal fluid of patients with Alzheimer type dementia (ATD) and those with Binswanger type vascular dementia (VDBT), and changes in these indoleamine concentrations 2 weeks after administration of citalopram, a 5-HT uptake inhibitor. The concentrations of total 5-HT (p < 0.005) and kynurenine (p < 0.005) were significantly decreased in ATD patients in comparison to those of the controls. After citalopram administration, there was a remarkable increase in 5-HT concentration (249%, p < 0.0001) and a significant decrease in 5-HIAA concentration (22%, p < 0.02). In the VDBT patients, only 5-HT showed a significant decrease (p < 0.005) in comparison to the control values. It also increased significantly (214%) after citalopram administration. The 5-HT/tryptophan and kynurenine/tryptophan ratios were not correlated for the controls, but did significantly for the ATD and VDBT patients; after citalopram treatment, the increase in 5-HT/tryptophan was correlated significantly with that of kynurenine/tryptophan for ATD, but not for VDBT. These results suggest that both the serotonin and kynurenine pathways are impaired in ATD; whereas, the serotonin pathway alone is in VDBT, and that these impairments are ameliorated by the administration of citalopram.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8526997     DOI: 10.1007/bf02259654

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  6 in total

1.  Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients.

Authors:  H Tohgi; T Abe; M Saheki; K Yamazaki; T Murata
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio.

Authors:  Tomasz Kocki; Sebastian Wnuk; Renata Kloc; Janusz Kocki; Björn Owe-Larsson; Ewa M Urbanska
Journal:  J Neural Transm (Vienna)       Date:  2011-06-10       Impact factor: 3.575

3.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

Review 4.  Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.

Authors:  Alok Joshi; Da-Hui Wang; Steven Watterson; Paula L McClean; Chandan K Behera; Trevor Sharp; KongFatt Wong-Lin
Journal:  Neuropharmacology       Date:  2020-05-04       Impact factor: 5.250

5.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 6.  Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development.

Authors:  Knut Biber; Anindya Bhattacharya; Brian M Campbell; Justin R Piro; Michael Rohe; Roland G W Staal; Robert V Talanian; Thomas Möller
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.